Acute cardiac care & resuscitation

Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial

JACC AdvPublished Secondary analysis of the DEFENDER randomised trial

Authors' conclusion

No treatment effect heterogeneity was observed based on intensive care unit admission reason.

Study context

Population
Critically ill patients with acute organ dysfunction, admitted for CV vs non-CV reasons162 CV, 345 non-CV
Participants
507 patients
Comparison
Dapagliflozin vs standard care, CV vs non-CV ICU admissions
Primary endpoint
Hierarchical composite of:
  1. Hospital mortality
  2. Kidney replacement therapy initiation
  3. ICU length of stay
analysed by win ratio
Follow-up
Through 28 days
Methodological detailssubgroup analysis
  • Subgroup analysis

Primary result

As reported in the abstract

Hierarchical composite of:
  1. Hospital mortality
  2. KRT initiation
  3. ICU length of stay
(win ratio); by admission reason
· 28 days
Win ratio (95% CI)
Cardiovascularcardiovascular subgroup; dapagliflozinvs standard care
0.94(0.77–1.15)
Noncardiovascularnoncardiovascular subgroup; dapagliflozinvs standard care
1.05(0.91–1.21)

Further findings

OutcomeDifference (mL/day) (95% CrI)
Daily parameters in CV patients (Bayesian mixed models)Dapagliflozinvs Standard careUrine output, CrI212 (30–392)
Daily parameters in CV patients (Bayesian mixed models)Dapagliflozinvs Standard careFluid balance, CrI−237 (−447 to −26)

μg/kg/min

Daily parameters in CV patients (Bayesian mixed models) — Norepinephrine requirement increase
0.01
Daily parameters in CV patients (Bayesian mixed models) — Dobutamine requirement increase
0.43
  • Daily parameters in CV patients (Bayesian mixed models): 134 CV patients analysed
  • Daily parameters in CV patients (Bayesian mixed models): 95% credible interval

Safety

Serious adverse events

Similar between arms in both subgroups

Original publication

Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial. JACC Adv. Published 19 December 2025. doi:10.1016/j.jacadv.2025.102459

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.